Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.

Nomdedéu J, Hoyos M, Carricondo M, Esteve J, Bussaglia E, Estivill C, Ribera JM, Duarte R, Salamero O, Gallardo D, Pedro C, Aventin A, Brunet S, Sierra J.

Leuk Res. 2012 Aug;36(8):990-7. doi: 10.1016/j.leukres.2012.03.019. Epub 2012 Apr 19.

PMID:
22520341
2.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
3.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

4.

[Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].

Jia ZX, Zhou M, Chao HY, Lu XZ, Zhang R, Cen L, Xiao R, Jiang NK.

Zhonghua Xue Ye Xue Za Zhi. 2012 May;33(5):397-401. Chinese.

PMID:
22781800
5.

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A.

Blood. 2010 Jul 29;116(4):614-6. doi: 10.1182/blood-2010-03-272146. Epub 2010 Apr 26.

6.

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.

Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU.

J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5.

7.

[Clinical significance of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].

Mi RH, Lu XD, Wei XD, Fan RH, Yin QS, Hu JY, Wang Q, Song YP.

Zhonghua Xue Ye Xue Za Zhi. 2011 Sep;32(9):610-3. Chinese.

PMID:
22338155
8.

IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.

Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, Yang J, Wang CZ, Chai HY, Qian Z, Xiao GF, Xu WR.

Ann Hematol. 2012 Apr;91(4):519-25. doi: 10.1007/s00277-011-1352-7. Epub 2011 Oct 14.

PMID:
21997850
9.

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.

Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC, Gale RE.

Blood. 2011 Jul 14;118(2):409-12. doi: 10.1182/blood-2010-12-322479. Epub 2011 May 19.

10.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Löwenberg B, Valk PJ.

Blood. 2010 Sep 23;116(12):2122-6. doi: 10.1182/blood-2009-11-250878. Epub 2010 Jun 10.

11.

[Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].

Wang RX, Wu DP, Chen SN, He J, Xu Y, Wang XL, Yin J, Tian H, Tian XP, Sun AN.

Zhonghua Yi Xue Za Zhi. 2013 Mar 12;93(10):751-5. Chinese.

PMID:
23755812
12.

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Wagner K, Damm F, Göhring G, Görlich K, Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar AA, Fiedler W, Kirchner HH, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A, Krauter J.

J Clin Oncol. 2010 May 10;28(14):2356-64. doi: 10.1200/JCO.2009.27.6899. Epub 2010 Apr 5.

PMID:
20368538
13.

IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype.

Chao HY, Jia ZX, Chen T, Lu XZ, Cen L, Xiao R, Jiang NK, Ying JH, Zhou M, Zhang R.

Int J Lab Hematol. 2012 Oct;34(5):502-9. doi: 10.1111/j.1751-553X.2012.01422.x. Epub 2012 Apr 11.

PMID:
22494415
14.

[Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].

Shang Z, Wang D, Xiao M, Wang J, Li TJ, Zhao YC, Li CR, Zhou JF.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):607-12. doi: 10.7534/j.issn.1009-2137.2013.03.014. Chinese.

PMID:
23815907
15.

The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.

Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Wu SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo KT, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF.

Leukemia. 2011 Feb;25(2):246-53. doi: 10.1038/leu.2010.267. Epub 2010 Nov 16.

PMID:
21079611
16.

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C.

J Clin Oncol. 2010 Aug 10;28(23):3717-23. doi: 10.1200/JCO.2010.28.2285. Epub 2010 Jul 12.

PMID:
20625116
17.

IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.

Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.

Eur J Haematol. 2014 Jun;92(6):471-7. doi: 10.1111/ejh.12271. Epub 2014 Mar 3.

PMID:
24443894
18.

Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.

Liang DC, Liu HC, Yang CP, Jaing TH, Hung IJ, Yeh TC, Chen SH, Hou JY, Huang YJ, Shih YS, Huang YH, Lin TH, Shih LY.

Blood. 2013 Apr 11;121(15):2988-95. doi: 10.1182/blood-2012-06-436782. Epub 2013 Jan 30.

19.

Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.

Ibáñez M, Such E, Cervera J, Luna I, Gómez-Seguí I, López-Pavía M, Dolz S, Barragán E, Fuster O, Llop M, Rodríguez-Veiga R, Avaria A, Oltra S, Senent ML, Moscardó F, Montesinos P, Martínez-Cuadrón D, Martín G, Sanz MA.

J Mol Diagn. 2012 Nov;14(6):594-601. doi: 10.1016/j.jmoldx.2012.06.006. Epub 2012 Aug 25. Erratum in: J Mol Diagn. 2013 Mar;15(2):280.

PMID:
22929312
20.

Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.

Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R.

Am J Clin Pathol. 2011 Jan;135(1):35-45. doi: 10.1309/AJCPD7NR2RMNQDVF.

Supplemental Content

Support Center